AHA/ASA Science Advisory Expansion of the Time Window for Treatment of Acute Ischemic Stroke With Intravenous Tissue Plasminogen Activator A Science Advisory From the American Heart Association/American Stroke Association (original) (raw)
AI-generated Abstract
This advisory discusses the expansion of the time window for administering intravenous recombinant tissue plasminogen activator (rtPA) in treating acute ischemic stroke beyond the currently approved 3-hour limit. It highlights findings from the European Cooperative Acute Stroke Study (ECASS)-3, supporting rtPA use within a 3 to 4.5-hour window, and outlines specific eligibility criteria for patients receiving treatment in this expanded timeframe. The advisory emphasizes that while a longer time frame has been scientifically evaluated, the importance of early treatment initiation remains critical to optimize patient outcomes.
Sign up for access to the world's latest research.
checkGet notified about relevant papers
checkSave papers to use in your research
checkJoin the discussion with peers
checkTrack your impact
Loading Preview
Sorry, preview is currently unavailable. You can download the paper by clicking the button above.